問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital (在職)

Division of Hematology & Oncology

Division of General Internal Medicine

Division of Thoracic Medicine

Division of Hematology & Oncology

Division of Hematology & Oncology

Division of Pediatrics

Digestive System Department

Kaohsiung Municipal Ta-Tung Hospital

Division of Hematology & Oncology

更新時間：2023-09-19

蕭惠樺Hsiao, Hui-Hua
  • Principal Investigator
  • Clinical Trial Experience (year) 17 years 9 個月

  • hsiaokmuh@gmail.com

Recruiting Trial

64Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

蕭惠樺

List

110Cases

2021-03-17 - 2027-01-15

Phase III

Active
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)

  • Condition/Disease

    Lymphoma, Mantle-Cell

  • Test Drug

    錠劑

Participate Sites
8Sites

Recruiting8Sites

2021-12-13 - 2026-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2022-04-01 - 2027-03-26

Phase III

Completed
A Multicenter, Randomized, Open-label, Blinded Endpoint Evaluation, Phase 3 Study Comparing the Effect of Abelacimab Relative to Apixaban on Venous Thromboembolism (VTE) Recurrence and Bleeding in Patients With Cancer Associated VTE

  • Condition/Disease

    Venous Thromboembolism

  • Test Drug

    注射劑

Participate Sites
8Sites

Recruiting8Sites

2021-11-01 - 2028-04-14

Phase III

Completed
A Randomized, Open-Label, Phase 3 Trial of Epcoritamab vs Investigator’s Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma

  • Condition/Disease

    Diffuse Large B-cell Lymphoma

  • Test Drug

    皮下注射劑

Participate Sites
5Sites

Recruiting5Sites

2022-04-01 - 2027-03-26

Phase III

Completed
A Multicenter, Randomized, Open-label, Blinded Endpoint Evaluation, Phase 3 Study Comparing the Effect of Abelacimab vs. Dalteparin on Venous Thromboembolism (VTE) Recurrence and Bleeding in Patients With GI/GU Associated VTE

  • Condition/Disease

    Venous Thromboembolism

  • Test Drug

    液劑

Participate Sites
7Sites

Recruiting7Sites

2022-02-01 - 2026-12-31

Phase II/III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2021-12-01 - 2025-06-30

Phase I/II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2020-07-31 - 2021-12-07

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2022-02-01 - 2026-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2022-08-25 - 2025-12-19

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

1 3 4 5 6 7 11
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB